Hydrea

Hydrea

hydroxycarbamide

Manufacturer:

Bristol-Myers Squibb

Distributor:

DKSH
Concise Prescribing Info
Contents
Hydroxyurea
Indications/Uses
Melanoma, resistant chronic myelocytic leukemia & recurrent, metastatic or inoperable carcinoma of the ovary. Used concomitantly w/ irradiation therapy in primary squamous cell (epidermoid) carcinomas of the head & neck (excluding the lip) & carcinoma of the cervix.
Dosage/Direction for Use
Solid tumors Continuous therapy: 20-30 mg/kg daily as a single dose. Intermittent therapy: 80 mg/kg as single doses given every 3rd day. Carcinoma of the head, neck & cervix Concomitant therapy w/ irradiation: 80 mg/kg in single doses given every 3rd day. Resistant chronic myelocytic leukemia Continuous therapy: 20-30 mg/kg daily as a single dose.
Contraindications
Patients w/ bone marrow depression ie, leukopenia, thrombocytopenia, severe anemia.
Special Precautions
Close supervision in hydroxyurea therapy eg, complete blood & bone marrow exam (interrupt therapy until values rise significantly to normal level), kidney & liver function. Renal dysfunction. Avoid concomitant use w/ didanosine & stavudine.
Adverse Reactions
Bone marrow depression (leukopenia, anemia, occasionally thrombocytopenia); rarely, GI symptoms, dermatologic reactions, headache, dizziness, disorientation, hallucinations, convulsions, temporary renal tubular function impairment.
Drug Interactions
Concurrent use w/ other myelosuppressive agents or radiation therapy may increase likelihood of bone marrow suppression.
ATC Classification
L01XX05 - hydroxycarbamide ; Belongs to the class of other antineoplastic agents. Used in the treatment of cancer.
Presentation/Packing
Form
Hydrea cap 500 mg
Packing/Price
100's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in